A highly innovative, personalized cell-based treatment for a high-risk form of the most common childhood cancer continues to move through clinical trials. Pediatric oncologists from Children’s Hospital of Philadelphia today reported new results using T cell immunotherapy against relapsed or refractory acute lymphoblastic leukemia (ALL). The physician-scientists presented findings at the annual meeting of the American Society…